141 related articles for article (PubMed ID: 37261572)
1. Comparative cost-effectiveness of nivolumab first-line and second-line therapy for advanced esophageal cancer in Japan.
Kashiwa M
Eur J Health Econ; 2024 Apr; 25(3):459-470. PubMed ID: 37261572
[TBL] [Abstract][Full Text] [Related]
2. Difference in Cost-Effectiveness between First-Line and Third-Line or Later Nivolumab Therapy in Patients with HER2-Negative, Unresectable, Advanced or Recurrent Gastric or Gastro-Esophageal Junction Cancer in Japan.
Kashiwa M; Matsushita R
Biol Pharm Bull; 2022; 45(7):895-903. PubMed ID: 35786597
[TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness of First-Line Nivolumab Plus Ipilimumab Combination Therapy in Advanced Non-Small-Cell Lung Cancer in Japan.
Mo X; Moriwaki K; Morimoto K; Shimozuma K
Clin Drug Investig; 2022 Jul; 42(7):599-609. PubMed ID: 35675029
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of nivolumab plus chemotherapy vs chemotherapy for patients with unresectable advanced or metastatic HER2-negative gastric or gastroesophageal junction or esophageal adenocarcinoma in Japan.
Morimoto K; Moriwaki K; Shimozuma K; Nakayama T
J Gastroenterol; 2023 Dec; 58(12):1188-1197. PubMed ID: 37725256
[TBL] [Abstract][Full Text] [Related]
5. Cost-Effectiveness of Nivolumab-Ipilimumab Combination Therapy Compared with Monotherapy for First-Line Treatment of Metastatic Melanoma in the United States.
Oh A; Tran DM; McDowell LC; Keyvani D; Barcelon JA; Merino O; Wilson L
J Manag Care Spec Pharm; 2017 Jun; 23(6):653-664. PubMed ID: 28530525
[TBL] [Abstract][Full Text] [Related]
6. Economic evaluation of nivolumab combined with ipilimumab in the first-line treatment of advanced melanoma in Japan.
Paly VF; Hikichi Y; Baker T; Itakura E; Chandran N; Harrison J
J Med Econ; 2020 Dec; 23(12):1542-1552. PubMed ID: 33000994
[TBL] [Abstract][Full Text] [Related]
7. Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab Combination Therapy as First-line Treatment for Advanced Renal Cell Carcinoma in Japan.
Maeda T; Moriwaki K; Morimoto K; Mo X; Yoshioka T; Goto R; Shimozuma K
Value Health Reg Issues; 2024 Mar; 40():118-126. PubMed ID: 38194896
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of nivolumab combination therapy in the first-line treatment for advanced esophageal squamous-cell carcinoma.
Liu S; Dou L; Wang K; Shi Z; Wang R; Zhu X; Song Z; Li S
Front Oncol; 2022; 12():899966. PubMed ID: 35936686
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of Nivolumab-Ipilimumab Combination Therapy for the Treatment of Advanced Non-Small Cell Lung Cancer.
Courtney PT; Yip AT; Cherry DR; Salans MA; Kumar A; Murphy JD
JAMA Netw Open; 2021 May; 4(5):e218787. PubMed ID: 33938936
[TBL] [Abstract][Full Text] [Related]
10. Cost-Effectiveness Analysis of Atezolizumab versus Platinum-Based Chemotherapy as First-Line Treatment for Patients with Unresectable Advanced Non-small Cell Lung Cancer with PD-L1 Expression Status in Japan.
Chisaki Y; Nakano H; Minamide J; Yano Y
Clin Drug Investig; 2023 Nov; 43(11):839-850. PubMed ID: 37891362
[TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness Analysis of Pembrolizumab in Patients With Advanced Esophageal Cancer Based on the KEYNOTE-181 Study.
Zhan M; Xu T; Zheng H; He Z
Front Public Health; 2022; 10():790225. PubMed ID: 35309225
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of nivolumab plus ipilimumab plus two cycles of platinum-doublet chemotherapy versus platinum-doublet chemotherapy alone for first-line treatment of stage IV or recurrent non-small cell lung cancer in the United States.
Polyzoi M; Sandhu H; Maervoet J; Yuan Y; Chaudhary MA; Varol N; Lee A; Dale P; Jones C; Lubinga SJ; Penrod JR
J Med Econ; 2022; 25(1):660-668. PubMed ID: 35658806
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of serplulimab plus chemotherapy in the first-line treatment for PD-L1-positive esophageal squamous cell carcinoma in China.
Liu S; Jiang N; Dou L; Li S
Front Immunol; 2023; 14():1172242. PubMed ID: 37215110
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of trifluridine/tipiracil against nivolumab for heavily pretreated metastatic gastric cancer in Japan.
Takushima Y; Igarashi A; Yoshihara H; Shitara K; Doi T
Jpn J Clin Oncol; 2021 Aug; 51(9):1383-1390. PubMed ID: 34128042
[TBL] [Abstract][Full Text] [Related]
15. First-line nivolumab plus ipilimumab or chemotherapy
Cao X; Cai H; Li N; Zheng B; Zheng Z; Liu M
Ther Adv Med Oncol; 2022; 14():17588359221122733. PubMed ID: 36147862
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of nivolumab plus ipilimumab versus chemotherapy as first-line therapy in advanced non-small cell lung cancer.
Shu Y; Ding Y; Li F; Zhang Q
Int Immunopharmacol; 2023 Jan; 114():109589. PubMed ID: 36700770
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of nivolumab-chemotherapy as first-line therapy for locally advanced/metastatic gastric cancer: a United States payer perspective.
Marupuru S; Arku D; Axon DR; Villa-Zapata L; Yaghoubi M; Slack MK; Warholak T
Expert Rev Pharmacoecon Outcomes Res; 2023; 23(7):831-841. PubMed ID: 37243493
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of first-line immunotherapies for advanced non-small cell lung cancer.
Yang SC; Ou HT; Su WC; Wang SY
Cancer Med; 2023 Apr; 12(7):8838-8850. PubMed ID: 36653947
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of nivolumab plus ipilimumab versus platinum-doublet chemotherapy for first-line treatment of stage IV or recurrent non-small cell lung cancer in the United States.
Berling M; Chaudhary MA; Yuan Y; Varol N; Dale P; Testa E; Klint J; Lee A; Lubinga SJ; Penrod JR
J Med Econ; 2022; 25(1):703-711. PubMed ID: 35659172
[TBL] [Abstract][Full Text] [Related]
20. A Cost-Effectiveness Analysis of Nivolumab and Ipilimumab Versus Sunitinib in First-Line Intermediate- to Poor-Risk Advanced Renal Cell Carcinoma.
Reinhorn D; Sarfaty M; Leshno M; Moore A; Neiman V; Rosenbaum E; Goldstein DA
Oncologist; 2019 Mar; 24(3):366-371. PubMed ID: 30710066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]